Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. Founded in 1995, Oncodesign Services mission’ is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing, Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.). Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities. As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates. Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program. Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m² of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.